Active Ingredient(s):Osimertinib FDA Approved: * November 13, 2015 Pharm Company: *ASTRAZENECA PHARMS Category:Cancer
Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
The most common side effects include diarrhea, rash, musculoskeletal pain, dry skin, skin inflammation around nails, sore mouth, fatigue and cough.
Osimertinib was approved for medical use in the Unit...
* May have multiple approval dates, manufacturers, or labelers.